CMRA Statistics
Total Valuation
Comera Life Sciences Holdings has a market cap or net worth of 6,148. The enterprise value is 3.12 million.
| Market Cap | 6,148 |
| Enterprise Value | 3.12M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Comera Life Sciences Holdings has 30.74 million shares outstanding.
| Shares Outstanding | 30.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +20.67% |
| Owned by Insiders (%) | 53.85% |
| Owned by Institutions (%) | 6.17% |
| Float | 8.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.33 |
| EV / Sales | 3.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.46 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 5.49.
| Current Ratio | 0.90 |
| Quick Ratio | 0.64 |
| Debt / Equity | 5.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | -303.72 |
Financial Efficiency
Return on equity (ROE) is -1,629.02% and return on invested capital (ROIC) is -324.51%.
| Return on Equity (ROE) | -1,629.02% |
| Return on Assets (ROA) | -119.35% |
| Return on Capital (ROIC) | -324.51% |
| Revenue Per Employee | 76,954 |
| Profits Per Employee | -719,482 |
| Employee Count | 13 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.97% in the last 52 weeks. The beta is 0.04, so Comera Life Sciences Holdings's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 |
| 52-Week Price Change | -99.97% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.12 |
| Relative Strength Index (RSI) | 30.65 |
| Average Volume (20 Days) | 10,301 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.53 |
Income Statement
In the last 12 months, Comera Life Sciences Holdings had revenue of 1.00 million and -9.35 million in losses. Loss per share was -0.48.
| Revenue | 1.00M |
| Gross Profit | 735,520 |
| Operating Income | -7.65M |
| Pretax Income | -9.01M |
| Net Income | -9.35M |
| EBITDA | -7.55M |
| EBIT | -7.65M |
| Loss Per Share | -0.48 |
Balance Sheet
The company has 1.77 million in cash and 561,468 in debt, giving a net cash position of 1.21 million or 0.04 per share.
| Cash & Cash Equivalents | 1.77M |
| Total Debt | 561,468 |
| Net Cash | 1.21M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 102,264 |
| Book Value Per Share | -0.14 |
| Working Capital | -301,923 |
Cash Flow
In the last 12 months, operating cash flow was -6.66 million and capital expenditures -94,009, giving a free cash flow of -6.76 million.
| Operating Cash Flow | -6.66M |
| Capital Expenditures | -94,009 |
| Free Cash Flow | -6.76M |
| FCF Per Share | -0.22 |
Margins
| Gross Margin | 73.52% |
| Operating Margin | -764.38% |
| Pretax Margin | -900.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -675.24% |
Dividends & Yields
Comera Life Sciences Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -212.24% |
| Shareholder Yield | -212.24% |
| Earnings Yield | -238,993.50% |
| FCF Yield | -109,882.21% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Comera Life Sciences Holdings has an Altman Z-Score of -22.51. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.51 |
| Piotroski F-Score | n/a |